A Study to Provide Expanded Access for the Treatment of Cancers with Rearranged During Transfection (RET) Activation

Overview

About this study

The purpose of this study is to provide expanded access for patients with cancer with RET activation who are ineligible for an ongoing LOXO-292 clinical trial or have other considerations that prevent access to LOXO-292 through an existing clinical trial.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria: 

  • Diagnosis of cancer with RET activation, who are not eligible for an ongoing LOXO-292 clinical trial and are medically suitable for treatment with LOXO-292 .

Exclusion Criteria:

  • Currently enrolled in an ongoing clinical study of LOXO-292 or another RET inhibitor.
  • Given the nature and objectives of this EAP, in principle there are no reasons for the exclusion of protected patients. Nevertheless, inclusion of such patients will be dependent on the Investigator’s judgement. This will be related to the level of impairment, as assessed by the Investigator, and its foreseen impact on a patient’s ability to comply with the protocol. In case of inclusion of such patients, informed consent would need to be administered according to ICH GCP sections 1.37 and/or 4.8.12, as applicable.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Jacksonville, Fla.

Mayo Clinic principal investigator

Victor Bernet, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Rochester, Minn.

Mayo Clinic principal investigator

John Morris, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Nina Karlin, M.D.

Closed for enrollment

Contact information:

Cancer Center Clinical Trials Referral Office

(855) 776-0015

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20470856

Mayo Clinic Footer